SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is seeing significant retail and institutional interest as community members track the 80th clinical event in the REGAL trial, viewing it as the critical catalyst for potential acquisition or data-driven gains. Traders are actively debating the timing of upcoming conference presentations while closely monitoring heavy institutional buying and high short interest, fueling a intense speculative environment surrounding the companys dual oncology platforms.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is gaining momentum as investors position themselves ahead of the SpaceX IPO, with community sentiment fueled by the company's role as a key infrastructure provider in the space sector. Discussion is centered on its record-breaking contract backlog and potential synergy with upcoming orbital data center projects, driving a surge in institutional interest and trading volume.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is facing a significant sell-off as investors grapple with sector-wide rotation away from legacy SaaS, despite the company's aggressive stock buyback program and integration of Agentforce AI. While some community members view the current valuation as an extreme discount for a free cash flow generator, others remain wary of long-term disruption risks and persistent bearish momentum in the software space.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending due to the launch of 'Ford Energy,' a new subsidiary focusing on battery energy-storage systems for data centers, utilities, and industrial customers to capture growing AI-driven power demand. Community members are actively debating the potential valuation re-rating from an automaker to an AI infrastructure play, while others remain cautious given past recalls and the volatile nature of the company's previous strategic pivots.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is currently a primary focus for investors as the company aggressively pivots toward AI-driven revenue, with strong community sentiment centered on the growth of its AI cloud infrastructure and autonomous driving division. While some market participants express caution regarding legacy ad business performance and macroeconomic tensions, bulls are actively tracking the potential of Baidu's in-house AI chips and agentic AI platforms to catalyze a significant re-rating of the stock.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is currently trending as investors closely monitor its transition into a significant U.S. solar manufacturing player, fueled by optimism around domestic production capacity and data-center power demand. The community is actively debating the company's long-term potential versus short-term volatility, with many focusing on whether recent earnings reports and management's expansion plans provide enough momentum to sustain a re-rating in price.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike Inc is experiencing intense selling pressure, with the stock trading at multi-year lows as market participants express deep skepticism over its turnaround efforts, leadership, and loss of market share. While some retail traders are betting on a recovery fueled by upcoming catalysts like the World Cup and potential tariff relief, many others are aggressively shorting the name, citing concerns over inventory, declining demand, and a perceived loss of brand resonance.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark Inc. is currently a focal point for investors as it navigates a transition from pure Bitcoin mining toward AI infrastructure, with community discourse heavily split between optimism over its 1.8GW power portfolio and frustration over the delay in announcing expected hyperscaler data center deals. Investors are closely tracking upcoming earnings for clear guidance on the AI strategy and potential management accountability, while high short interest continues to fuel intense debate regarding the stock's future volatility and squeeze potential.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors react to a White House executive order that aims to accelerate FDA review timelines for psychedelic-based treatments, significantly boosting sentiment around the company's lead psilocybin candidate, COMP360. Community discussion is heavily focused on the potential for imminent priority vouchers to compress approval pathways, with many highlighting COMP360's advanced clinical trial status and the potential for a massive sector re-valuation.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is generating intense community buzz as investors debate its valuation ahead of key earnings, with many traders actively positioning for a potential squeeze due to high short interest and anticipation of growth in its autonomous driving and robotics sectors. While sentiment remains polarized between those betting on long-term AI-driven upside and others skeptical of near-term execution, recent positive contract news and potential integration milestones have fueled significant call option volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need...

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease...

Lifesci Capital Has Pessimistic Outlook of RCKT Q1 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Lifesci Capital cut their Q1 2026 EPS estimates for shares of Rocket Pharmaceuticals in a research report issued on Thursday, April 16th...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Brokerages

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) has received a consensus rating of "Hold" from the eighteen ratings firms that are presently covering the stock, Marketbeat Ratings...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Short Interest Update

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 18,580,923 shares, an increase of 26.5% from the March 15th total of 14,693,507 shares. Currently, 22.6% of the company's...

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving Average   - Here's What Happened

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Passes Below 50-Day Moving Average - Here's What Happened...

Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 73.6% during the third quarter, according to its most recent disclosure with the SEC...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Bank of America Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Bank of America upped their target price on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Monday...

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RCKT News

RCKTRocket Pharmaceuticals Inc